Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Palisade Bio, Inc. is a biotechnology company focused on developing innovative therapeutics for patients with gastrointestinal diseases. Its lead product candidate, PB2452, is designed to reverse the effects of anticoagulation therapy, targeting a significant unmet medical need in emergency care settings. The company's unique approach leverages its proprietary technology platform to create biologics that can be rapidly developed and manufactured.
Palisade Bio primarily aims to generate revenue through the commercialization of its lead product PB2452, once it receives regulatory approval. The company holds a competitive advantage through its proprietary technology that enables rapid development cycles and the potential for high margins once products reach the market.
Clinical trial results for PB2452, particularly Phase 2 and Phase 3 outcomes
Regulatory approvals from the FDA or EMA
Partnership announcements with larger pharmaceutical companies
Market adoption rates post-launch
Regulatory changes that could impact drug approval processes
Technological disruption in drug development methodologies
Emerging therapies that could provide similar benefits to PB2452
Increased competition from larger biotech firms with more resources
High cash burn rate leading to potential liquidity issues if funding is not secured
Dependence on future financing rounds to support ongoing clinical trials
low - As a biotechnology firm, Palisade Bio's performance is less correlated with traditional economic cycles and more dependent on clinical outcomes and regulatory approvals.
Interest rates can affect the company's cost of capital for funding clinical trials, but given the lack of debt, the direct impact is minimal. Higher rates could dampen investor sentiment toward biotech stocks.
minimal - The company has no debt, which reduces its exposure to credit market fluctuations.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector may be attracted to Palisade Bio.
high - The stock has exhibited significant volatility, with a 1-year return of 227.9%, indicating high investor sentiment swings.